← Spero Therapeutics, Inc. (SPRO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Spero Therapeutics, Inc. (SPRO)
Pharmaceutical Preparations · market cap $73M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Spero Therapeutics (SPRO) is a small-cap pharmaceutical company with 32 employees and a $122M market cap, focused on antibacterial therapies. Its lead assets are TBP-PI-HBr and TBPM-PI-HBr, both in Phase 3 for urinary tract infections, with SPR720 in Phase 2 for nontuberculous mycobacterial pulmonary disease. The company holds $56.1M in cash with no net debt, and posted $67M in revenue and $9M net income in 2025.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SPR720 500 mg | Phase 2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) |
| TBP-PI-HBr | Phase 3 | Urinary Tract Infection |
| TBPM-PI-HBr | Phase 3 | Complicated Urinary Tract Infection |
Price & technical context
3-month
-45.7%
6-month
-51.0%
12-month
-39.3%
52-wk range
$1.11–$2.98
vs 50-day MA
-1.1%
vs 200-day MA
-43.6%
Realized vol
65.7%
Max drawdown
-63.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SPRO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.